Pfizer Sees Quarterly Sales Surge Boosted by COVID Vaccine and Pill
Pfizer Surpasses Q4 Expectations Amid Cost-Cutting Measures and Strong COVID Product Sales Pfizer’s fourth-quarter performance in 2023 has defied expectations, showcasing resilience in the face of criticism and market challenges. The pharmaceutical giant reported sales of $17.8 billion, surpassing the projected $17.3 billion, driven by robust sales of its COVID-19 vaccine and antiviral pill. … Read more